Parathyroidectomy Versus Cinacalcet Hydrochloride-Based Medical Therapy in the Management of Hyperparathyroidism in ESRD: A Cost Utility Analysis

American Journal of Kidney Diseases

Volumn 49, Issue 6, 2007, Pages 801-813

  Narayan, Rajeev ^a   Perkins, Robert M ^a   Berbano, Elizabeth P ^a   Yuan, Christina M ^a   Neff, Robert T ^a   Sawyers, Eric S ^a   Yeo, Fred E ^a   Vidal Trecan, Gwenaelle M ^b   Abbott, Kevin C ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

cinacalcet hydrochloride; cost utility; cost effectiveness; hyperparathyroidism; Medical decision analysis; parathyroid hormone (PTH); parathyroidectomy

Indexed keywords

CINACALCET;

ADULT; AGED; ARTICLE; DRUG COST; FEMALE; HUMAN; HYPERTHYROIDISM; INTERMETHOD COMPARISON; KIDNEY FAILURE; MALE; PARATHYROIDECTOMY; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; HUMANS; HYPERPARATHYROIDISM; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROIDECTOMY; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS; UNITED STATES;

EID: 34248998172     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.03.009     Document Type: Article

References (35)

1. Owda A., Elhwairis H., Narra S., Towery H., and Osama S. Secondary hyperparathyroidism in chronic hemodialysis patients: Prevalence and race. Ren Fail 25 (2003) 595-602
2. Locatelli F. The need for better control of secondary hyperparathyroidism. Nephrol Dial Transplant 19 suppl 5 (2004) SV15-SV19
3. Lorenzo V., Martin-Malo A., Perez-Garcia R., et al. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: A cross-sectional multicentre study. Nephrol Dial Transplant 21 (2006) 459-465
4. de Francisco A.L. Secondary hyperparathyroidism: Review of the disease and its treatment. Clin Ther 26 (2004) 1976-1993
5. Kestenbaum B., Andress D.L., Schwartz S.M., et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 66 (2004) 2010-2016
6. Cunningham J., Danese M., Olson K., Klassen P., and Chertow G.M. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68 (2005) 1793-1800
7. Wholesale Drug Prices (2006), AmerisourceBergen Corporation, Chesterbrook, PA (provided by Walter Reed Pharmacy), October
8. Moe S.M., Cunningham J., Bommer J., et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 20 (2005) 2186-2193
9. Lindberg J.S., Culleton B., Wong G., et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 16 (2005) 800-807
10. Block G.A., Martin K.J., de Francisco A.L., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350 (2004) 1516-1525
11. Dong B.J. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther 27 (2005) 1725-1751
12. Detsky A.S., Naglie G., Krahn M.D., Redelmeier D.A., and Naimark D. Primer on medical decision analysis: Part 2-Building a tree. Med Decis Making 17 (1997) 126-135
13. Sejean K., Calmus S., Durand-Zaleski I., et al. Surgery versus medical follow-up in patients with asymptomatic primary hyperparathyroidism: A decision analysis. Eur J Endocrinol 153 (2005) 915-927
14. Mokrzycki M.H., and Singhal A. Cost-effectiveness of three strategies of managing tunnelled, cuffed haemodialysis catheters in clinically mild or asymptomatic bacteraemias. Nephrol Dial Transplant 17 (2002) 2196-2203
15. Saab S., Brezina M., Gitnick G., Martin P., and Yee Jr. H.F. Hepatitis C screening strategies in hemodialysis patients. Am J Kidney Dis 38 (2001) 91-97
16. Strippoli G.F., Palmer S., Tong A., Elder G., Messa P., and Craig J.C. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis 47 (2006) 715-726
17. Richards M.L., Wormuth J., Bingener J., and Sirinek K. Parathyroidectomy in secondary hyperparathyroidism: Is there an optimal operative management?. Surgery 139 (2006) 174-180
18. Goodman W.G., Frazao J.M., Goodkin D.A., Turner S.A., Liu W., and Coburn J.W. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58 (2000) 436-445
19. Goodman W.G., Hladik G.A., Turner S.A., et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13 (2002) 1017-1024
20. Lindberg J.S., Moe S.M., Goodman W.G., et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 63 (2003) 248-254
21. Quarles L.D., Sherrard D.J., Adler S., et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14 (2003) 575-583
22. Harris R.Z., Padhi D., Marbury T.C., Noveck R.J., Salfi M., and Sullivan J.T. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 44 (2004) 1070-1076
23. Dotzenrath C., Cupisti K., Goretzki E., et al. Operative treatment of renal autonomous hyperparathyroidism: Cause of persistent or recurrent disease in 304 patients. Langenbecks Arch Surg 387 (2003) 348-354
24. Qunibi W.Y., Hootkins R.E., McDowell L.L., et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65 (2004) 1914-1926
25. Centers for Medicare & Medicaid Services: Average National Reimbursement Figures (2005), Department of Health and Human Services, Washington, DC (provided by WRAMC DRG Coordinator)
26. Ruda J., Stack Jr. B.C., and Hollenbeak C.S. The cost-effectiveness of sestamibi scanning compared to bilateral neck exploration for the treatment of primary hyperparathyroidism. Otolaryngol Clin North Am 37 (2004) 855-870 x-xi
27. McHenry C.R., Wilhelm S.M., and Ricanati E. Refractory renal hyperparathyroidism: Clinical features and outcome of surgical therapy. Am Surg 67 (2001) 310-316 discussion, 316-317
28. Whiting J.F., and Transplantation Outcomes Research Group. Standards for economic and quality of life studies in transplantation. Transplantation 70 (2000) 1115-1121
29. Tengs T.O., and Wallace A. One thousand health-related quality-of-life estimates. Med Care 38 (2000) 583-637
30. McFarlane P.A., Bayoumi A.M., Pierratos A., and Redelmeier D.A. The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int 64 (2003) 1004-1011
31. Furth S.L., Garg P.P., Neu A.M., Hwang W., Fivush B.A., and Powe N.R. Racial differences in access to the kidney transplant waiting list for children and adolescents with end-stage renal disease. Pediatrics 106 (2000) 756-761
32. Abbott K.C., Glanton C.W., and Agodoa L.Y. Body mass index and enrollment on the renal transplant waiting list in the United States. J Nephrol 16 (2003) 40-48
33. US Renal Data System. USRDS 2005 Annual Data Report (2005), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
34. Manns B., Stevens L., Miskulin D., Owen Jr. W.F., Winkelmayer W.C., and Tonelli M. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66 (2004) 1239-1247
35. White C.A., Jaffey J., and Magner P. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney Int 71 (2007) 312-317